MedTrace Logo

Effects of Cardiac Telerehabilitation During COVID-19 on Cardiorespiratory Capacities in Coronary Artery Disease Patients.

NCT05749744 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2023-03-03

No results posted yet for this study

Summary

After an acute coronary syndrome, an adapted cardiac rehabilitation program is necessary to restore or increase physical capacities and decrease cardiovascular risk. This multidisciplinary care combines physical training sessions and therapeutic education workshops.

The COVID-19 pandemic imposed restrictions such as the closure of rehabilitation centres. To remedy this problem, one solution was to adapt the existing program to a remote cardiac telerehabilitation, i.e., medical and paramedical supervision of rehabilitation sessions and therapeutic patient education meetings via digital tools. Recent studies have shown that it was a safe (no reported adverse effects), effective (similar gains in peak oxygen consumption compared to traditional cardiac rehabilitation and patient-adherence alternative.

Conditions

  • Cardiac Disease

Interventions

OTHER

cardiac telerehabilitation program by videoconference

* A video conference interview with an Adapted Physical Activity (APA) teacher before starting physical training * Exercise training for 3 weeks via distance coaching * Therapeutic patient education (TPE) workshops conducted remotely with 1 workshop per week. * Medical follow-up via teleconsultation * Psychological and/or dietetic follow-up if necessary. * Final assessment at 1 month with evaluation of aerobic metabolism, functional evaluation and final shared educational assessment (BEP). * Appointment with an association "Cœur et Santé" and "Sport-Santé 42" or setting up of an individual physical activity

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • David Hupin, MD · CHU SAINT-ETIENNE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05749744 on ClinicalTrials.gov